Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial

Exclusion Criteria

• •inability to undergone upper GI endoscopy or PH monitoring
• •presence of barret's esophagus or erosive esophagitis in upper GI endoscopy
• •presence of active peptic ulcer disease or any disease which affects the absorption of drugs such as inflammatory bowel disease
• •past history of esophageal or gastric surgery
• •esophageal stricture which needs dilation
• •administration of proton pomp inhibitors during 30 days before inclusion to the study
• •administration of H2 blockers, anticholinergics, sucralfate and pro-kinetics during the assessments for eligibility and also during the study
• •long time administration of non-steroidal anti-inflammatory drugs (NSAIDs)
• •administration of neuroleptic or antidepressant drugs during 30 days before inclusion to the study
• •known allergy to PPIs or SSRIs
• •presence of significant systemic disease such as scleroderma , diabet mellitus , peripheral and autonomic neuropathies and ...
• •pregnancy for females
• •presence of known psychiatric disorder such as depression , panic disorder or drug addiction according to the DSM-IV criteria